Deerfield Management’s Teva Pharmaceuticals TEVA Stock Holding History

Deerfield Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-550,000	Closed	-$36.1M	–	113
2015 Q4	$36.1M	Hold	550,000	–	–	1.46%	18
2015 Q3	$31.1M	Buy	+550,000	New	+$35.7M	1.2%	29
2014 Q1	–	Sell	-350,000	Closed	-$14M	–	137
2013 Q4	$14M	Hold	350,000	–	–	0.73%	48
2013 Q3	$13.2M	Buy	+350,000	New	+$13.7M	0.62%	58

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Deerfield Management's TEVA Position: Q4 2016 in Review

Deerfield Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 30,000 shares — an estimated $1.38M sold.

Deerfield Management first reported a position in TEVA in Q2 2013 and held it in 7 quarters. The position peaked at $53.5M in Q4 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Deerfield Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Deerfield Management sold 30,000 Teva Pharmaceuticals shares in Q4 2016, an estimated $1.38M.
Deerfield Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Deerfield Management's Teva Pharmaceuticals position peaked at $53.5M in Q4 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Deerfield Management's 13F filing for Q4 2016, filed 14 Feb 2017.